Apogee Therapeutics (APGE) Change in Cash (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Change in Cash data on file, last reported at $320.2 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 1018.33% year-over-year to $320.2 million in Q1 2026; TTM through Mar 2026 was $344.6 million, a 191.03% increase from a year earlier, with the FY2025 full-year figure at -$10.5 million, down 144.88% from the prior year.
• Change in Cash for Q1 2026 stood at $320.2 million, up from $23.6 million in the prior quarter.
• Over the last five years, Change in Cash for APGE reached as high as $367.1 million in Q1 2024 and fell as low as -$188.5 million in Q3 2024.
• Historically, Change in Cash has averaged $29.8 million across 5 years, with a median of -$2.4 million in 2022.
• On a YoY basis, Change in Cash climbed as much as 3577.7% in 2024 and fell as far as 995.41% in 2024.
• Year by year, Change in Cash stood at $149.3 million in 2022, then plunged by 146.65% to -$69.7 million in 2023, then jumped by 133.03% to $23.0 million in 2024, then grew by 2.72% to $23.6 million in 2025, then surged by 1254.97% to $320.2 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $320.2 million in Q1 2026, $23.6 million in Q4 2025, and -$16.6 million in Q3 2025.